Exact Mass: 327.1107
Exact Mass Matches: 327.1107
Found 69 metabolites which its exact mass value is equals to given mass value 327.1107,
within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error
0.0002 dalton.
N-(4-Hydroxycinnamoyl)tyrosine
Natural food antioxidant. Isolated from cocoa liquor (Theobroma cacao). N-(4-Hydroxycinnamoyl)tyrosine is found in cocoa and cocoa products and cocoa powder. N-(4-Hydroxycinnamoyl)tyrosine is found in cocoa and cocoa products. Natural food antioxidant. It is isolated from cocoa liquor (Theobroma cacao).
Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]-
1,3-Dioxolo(4,5-g)furo(2,3-b)quinoline, 9-methoxy-4-((3-methyl-2-butenyl)oxy)-
(S,E)-2-(3-(3,4-dihydroxyphenyl)acrylamido)-3-phenylpropanoic acid|2-[3-(3,4-dihydroxy-phenyl)-acryloylamino]-3-phenylpropionic acid|N-trans-caffeoyl-L-phenylalanine
8-Hydroxy-5,7-Dimethoxy-4-(4-methoxyphenyl)-2(1H)-quinolinone
C18H17NO5_L-Tyrosine, N-[(2Z)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]
C18H17NO5_L-Tyrosine, N-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]
Tranilast
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000700 - Analgesics C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D018926 - Anti-Allergic Agents Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects[1]. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells[2]. trans-Tranilast (trans-MK-341) is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis. Target: Angiotensin Receptor Tranilast has been approved in Japan and South Korea, since 1982, for the treatment of bronchial asthma, with indications for keloids and hypertrophic scar added in 1993. Tranilast is also used to treat asthma, autoimmune diseases, atopic and fibrotic pathologies, and can also inhibit angiogenesis. The antiproliferative properties of tranilast were found that tranilast elicited an inhibitory effect on fibroblast proliferation in vitro and also suppressed collagen production both in vitro and in vivo . Tranilast also reduced the release of chemical mediators from mast cells and suppressed hypersensitivity reactions. [1] Three-week-old C57Bl/10 and mdx mice received tranilast (~300 mg/kg) in their food for 9 weeks, after which fibrosis was assessed through histological analyses, and functional properties of tibialis anterior muscles were assessed in situ and diaphragm muscle strips in vitro. Tranilast administration did not significantly alter the mass of any muscles in control or mdx mice, but it decreased fibrosis in the severely affected diaphragm muscle by 31\% compared with untreated mdx mice (P< 0.05) [2].
